Completed US$7.7 million financing and reverse takeover to take Company public Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp . (TSXV: CNVI) (“ Conavi Medical ” or the “... Read More